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Objectives. This study sought to 1) assess the short-, medium-
and long-term prognostic power of peak oxygen consumption
(V˙O2) in patients with heart failure; 2) verify the consistency of a
nonmeasurable anaerobic threshold (AT) as a criterion of nonap-
plicability of peak V˙O2; 3) develop simple rules for the efficient use
of peak V˙O2 in individualized prognostic stratification and clinical
decision making.
Background. Peak V˙O2, when AT is identified, is among the
indicators for heart transplant eligibility. However, in clinical
practice the application of defined peak V˙O2 cutoff values to all
patients could be inappropriate and misleading.
Methods. Six hundred fifty-three patients consecutively consid-
ered for eligibility for heart transplantation were followed up.
Outcomes (cardiac death and urgent transplantation) were deter-
mined when all survivors had a minimum of 6 months of
follow-up.
Results. Contraindication to the exercise test identified very
high risk patients. The relatively small sample of women did not
allow inferences to be drawn. In men, peak V˙O2 stratified into
three levels (<210, 10 to 18 and >18 ml/kg per min) identified
groups at high, medium and low risk, respectively. The prognostic
power of peak V˙O2 <210 ml/kg per min was maintained even when
the AT was not detected. In patients in New York Heart Associa-
tion functional class III or IV, peak V˙O2 did not have prognostic
power. In patients in functional class I or II, peak V˙O2 stratifica-
tion was prognostically valuable, but less so at 6 than at 12 or 24
months. Age did not influence peak V˙O2 prognostic stratification.
Conclusions. A contraindication to exercise testing should be
considered a priority for listing patients for heart transplanta-
tion. Only in less symptomatic male patients does a peak V˙O2
<210 ml/kg per min identify short-, medium- and long-term high
risk groups. A peak V˙O2 >18 ml/kg per min implies good
prognosis with medical therapy.
(J Am Coll Cardiol 1998;31:766–75)
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In patients with chronic heart failure (HF), peak oxygen
consumption (V˙O2), defined as the oxygen uptake at the
maximal level of tolerated exercise, is a descriptive indicator
with both prognostic power and decisional implications. A
continuous variable, peak V˙O2 has been categorized by many
investigators (1–11) for practical purposes, and the prognostic
power of the various V˙O2 cutoff points (10, 12, 14, 16 and
18 ml/kg per min) has been repeatedly confirmed in published
reports (1–11). In a study considered the cornerstone of the
validation of the prognostic power of peak V˙O2, Mancini et al.
(2) found that patients with a peak V˙O2 #10 ml/kg per min had
the worst prognosis. The other cutoff values proposed for risk
stratification were .10 to 14, .14 to 18 and .18 ml/kg per
min. As a decisional indicator, peak V˙O2 appears in the first
statement of the 24th Bethesda Conference (12) and in several
other reports and statements as an indicator for heart trans-
plant eligibility (2,13–19).
Peak V˙O2 should be considered only after the anaerobic
threshold (AT) is detected, thus guaranteeing nearly maximal
exercise performance. Mancini et al. (2), for instance, included
in their survival analysis only patients whose AT could be
identified for at least one of two exercise tests. However, in
daily clinical practice, AT goes undetected in a large propor-
tion of patients with a low peak V˙O2.
Despite such drawbacks, published studies have brought
about both increasing use of cardiopulmonary exercise (CPX)
testing in clinical practice and a simplistic application of
defined peak V˙O2 cutoff values to all patients with chronic HF.
Intuitively, such a generalized application holds the risk of
inappropriateness or wide approximation.
The present study was conceived with the aim of reconsid-
ering and elucidating major issues regarding the use of peak
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V˙O2 as a routine prognostic and decisional indicator in chronic
HF. We intended to 1) verify the clinical applicability of the
stratification suggested by Mancini et al. (2) in a large group of
patients with moderate to severe chronic HF, consecutively
considered for eligibility for heart transplantation; 2) verify the
need for exclusion from peak V˙O2 prognostic stratification of
those patients without a determinable AT; 3) compare the
short- (6 months), medium- (12 months) and long-term (24
months) prognostic power of peak V˙O2; and 4) develop simple
rules, based on some common clinical indicators, for using
peak V˙O2 in individualized prognostic stratification and clinical
decision making.
Methods
Patients. All patients with chronic HF and a left ventricu-
lar ejection fraction ,40%, admitted for assessment or reas-
sessment of indications for heart transplantation at the Heart
Failure Unit of Montescano Medical Center or the Cardiolog-
ical Department of Molinette Hospital of Turin from March
1992 to October 1995, were enrolled in the study.
On admission, all patients were given individualized ther-
apy, which generally included angiotensin-converting enzyme
inhibitors, vasodilators (nitroprusside, isosorbide dinitrate, hy-
dralazine), digoxin, diuretic drugs, inotropic drugs (dopamine,
dobutamine, enoximone) when needed and, in the absence of
contraindications, antiacoagulants (international normalized
ratio 2 to 3) or antiplatelet agents. At the time of recruitment,
beta-adrenergic blocking agents were not yet considered rou-
tine therapy.
After therapeutic optimization, when patients were clini-
cally stable, a functional evaluation was performed that
included two-dimensional echocardiography; right heart cath-
eterization, performed with a Swan-Ganz catheter for ther-
modilution, introduced through the internal jugular vein
(Seldinger technique); and CPX testing, carried out on a
treadmill with a modified Naughton protocol (20) and with
simultaneous monitoring of respiratory gases by a CAD/NET
System 2001 Medical Graphics analyzer. The AT was defined
as one or more of the following: 1) the point at which the
ventilatory equivalent for oxygen (V˙E/V˙O2) was minimal, fol-
lowed by a progressive increase; or 2) the point after which the
respiratory gas exchange ratio exceeded the rest respiratory gas
exchange ratio; or 3) the point after which a nonlinear increase
in minute ventilation occurred relative to carbon dioxide
consumption. The peak V˙O2 cutoff values used were those
proposed by Mancini et al. (2): #10, .10 to 14, .14 to 18 and
.18 ml/kg per min.
Contraindications to CPX testing were symptomatic con-
gestion at rest and the reappearance of rest symptoms after
weaning from vasodilator or inotropic infusion treatment.
Admission to the heart transplantation waiting list followed the
current guidelines (12); absolute and relative contraindications
were considered according to standard practice (12).
All patients were closely followed up by means of clinical
examination and other tests (echocardiography, CPX). All
surviving patients had a minimum of 6 months of follow-up.
Cardiac events. Sudden death (if unexpected, occurring in
or out of the hospital within 1 h after the onset of, or change
in, symptoms or during sleep in a patient who was symptom-
atically stable during the 24 h before death); progressive
HF-related death; other cardiac-related death, including acute
myocardial infarction and pulmonary embolism; and urgent
transplantation (in Status I patients) were considered cardiac
events.
Prognostic variables. To individualize the use of the prog-
nostic and decisional power of peak V˙O2, three descriptive
clinical indicators commonly used in clinical practice were
considered: gender, age and New York Heart Association
functional class.
Statistical analysis. All patients capable of performing the
CPX test were initially subclassified by gender. Within the
male group, survival analysis was performed separately for
subjects in whom the AT was detected and in those in whom it
was not. This analysis was carried out by stratifying patients
according to the cutoff points of Mancini et al. (2) and
estimating corresponding survival functions by the Kaplan-
Meier method. Data from patients who survived until the end
of the follow-up period, died of noncardiac-related causes or
underwent transplantation (except for Status I patients) were
treated as “censored” observations. Survival curves were com-
pared by the log-rank test. Besides allowing verification of the
robustness of the criteria of Mancini et al. (2) in a large group
of patients, this analysis also allowed the prognostic stratifica-
tion power of peak V˙O2 to be tested in patients without a
detected AT. The result was the identification of a subgroup of
patients, with or without a detected AT, for whom peak V˙O2
had a proven prognostic value. To refine this identification
process on the basis of the chosen clinical indicators, these
patients were then subclassified by age (#55 vs. .55 years),
and survival analysis was again performed to identify a further
subgroup, if existing, in which peak V˙O2 had a clear prognostic
value. Finally, the same procedure was repeated after classify-
ing patients by functional class (I to II vs. III to IV). The
overall procedural tree is summarized in Figure 1. In the final
subgroup, identification of the relative risk of each peak V˙O2
cutoff was estimated by Cox proportional hazards analysis
(peak V˙O2 cutoff was used as the explanatory variable in the
model), and the survival experience was further examined over
the first 6 months, 1 year and 2 years by the Kaplan-Meier
method.
Because of the small sample size of the women who
Abbreviations and Acronyms
AT 5 anaerobic threshold
CI 5 confidence interval
CPX 5 cardiopulmonary exercise
HF 5 heart failure
V˙O2 5 oxygen consumption
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performed the CPX test, survival analysis in this subgroup was
not carried out.
Results are expressed as mean value 6 SD. A probability
value ,0.05 was considered statistically significant. Statistical
analysis was performed with the SAS/STAT version 6.10
statistical package (SAS Institute Inc.).
Results
Patients. The clinical characteristics of the 653 patients
enrolled in the study are shown in Table 1. The average
follow-up period was 498.8 6 381 days (median 375). No
patient was lost to follow-up. Fourteen patients died of non-
cardiac causes. Fifty-six patients (43 men) could not perform
the CPX test because of clinical cardiac contraindications (20
of 24 patients in functional class IV were in this group). A
cardiac event (cardiac death or heart transplantation in Status
I patients) occurred in 77% of these patients, and in 70% (30
patients) within 100 days after the evaluation.
Female patients. Ninety-two of 105 female patients per-
formed the CPX test (55 in functional class I or II, 37 in
functional class III). Twenty-six patients of these 92 patients
died of cardiac causes and 1 of a noncardiac cause. Twenty-five
patients underwent heart transplantation, of whom 12 were in
Status I. In all, 38 events (cardiac death and heart transplan-
tation in Status I patients) occurred (Table 2).
During the exercise test, the AT was detected in only 26
patients and was not detected in 66. Because of the small
number of patients in both subgroups, survival analysis was not
carried out.
Male patients. In the male group, 505 of 548 patients
performed the CPX test. Among these 505 patients, 126 (25%)
died of cardiac causes and 11 (2.2%) of noncardiac causes; 93
(18.4%) underwent heart transplantation (24 were Status I). In
all, 150 events occurred (Table 2).
During the exercise test, the AT was detected in 324
patients (64%). The survival curves for these patients accord-
ing to the stratification of Mancini et al. (2) are shown in
Figure 2. A peak V˙O2 #10 ml/kg per min identified patients
with the worst prognosis (13 [59%] of 22 with a cardiac event),
Figure 1. Grouping procedure followed in the study. The two age
groups (#55 and .55 years) and New York Heart Association
(NYHA) functional class groups (I or II vs. III or IV) were derived
from 324 patients with and 48 without a detectable AT and peak V˙O2
#10 ml/kg per min (see text for details).
Table 1. Clinical Characteristics of 653 Study Patients
Age (yr) 52.1 6 9.0
Men/women 548/105
Etiology
Dilated cardiomyopathy 315 (48.2%)
Coronary ischemic disease 250 (38.2%)
Valvular disease 56 (8.6%)
Other 32 (5%)
Disease duration (mo) 46.1 6 8.6
NYHA functional class at evaluation
I 57 (9%)
II 339 (52%)
III 233 (36%)
IV 24 (3%)
LVEF (%) 24 6 7.7
Hemodynamic pattern (n 5 520)
Pulmonary wedge pressure (mm Hg) 20.1 6 9.9
Right atrial pressure (mm Hg) 6.2 6 4.8
Cardiac index (liters/min per m2) 2.2 6 0.5
CPX test (n 5 597 [505 men, 92 women])
Duration (min) 10.5 6 4.9
Peak V˙O2 (ml/kg per min) 14.7 6 5.4
Peak V˙O2 cutoff (% men/women)
#10 ml/kg per min 13.9%/33.7%
.10–14 ml/kg per min 33.3%/46.7%
.14–18 ml/kg per min 29.3%/9.8%
.18 ml/kg per min 23.6%/9.8%
AT (ml O2/kg per min) detected in 354
patients (324 men, 26 women)
13.3 6 4.3
Stop for fatigue 382 (64%)
Stop for dyspnea 101 (17%)
Other reasons 118 (19%)
Data presented are mean value 6 SD or number (%) of patients, unless
otherwise indicated. CPX 5 cardiopulmonary exercise; LVEF 5 left ventricular
ejection fraction; NYHA 5 New York Heart Association; V˙O2 5 oxygen uptake.
Table 2. Cardiac Events and Status at Follow-Up (mean 498.8 6
381 days)
Event
Men
(n 5 548)
[no. (%) of pts]
Women
(n 5 105)
[no. (%) of pts]
Death due to progressive HF 84 (15%) 17 (16%)
Sudden death 51 (9%) 8 (8%)
Other cardiac death 14 (2.5%) 1 (1%)
Noncardiac death 13 (2.5%) 1 (1%)
Tx status II 75 (14%) 13 (12%)
Tx status I 34 (6%) 12 (11%)
Survivors free of Tx 277 (51%) 53 (50.5%)
HF 5 heart failure; pts 5 patients; Tx 5 transplantation.
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whereas a peak V˙O2 .18 ml/kg per min identified patients with
the best prognosis (14 [15%] of 96 with a cardiac event). No
differences were found between survival of patients in the two
intermediate groups (32 of 98 with a peak V˙O2 .10 to 14 ml/kg
per min and 35 of 108 with a peak V˙O2 .14 to 18 ml/kg per min
had a cardiac event, p 5 0.66). We also repeated the analysis
using a narrower stratification (10 to 12.5, 12.5 to 15, 15 to 17.5,
17.5 to 20, .20 ml/kg per min), but survival curves of patients
with a peak V˙O2 in the range 10 to 17.5 ml/kg per min again did
not differ.
Because of the similarity of the survival curves of patients
with a peak V˙O2 10 to 14 and 14 to 18 ml/kg per min, we
considered these patients as a single group. The cardiac event
rates of the three resulting groups (patients with a peak
V˙O2 #10, 10 to 18, .18 ml/kg per min) were 62%, 33% and
15%, respectively. Death due to heart failure and Status I at
the time of transplantation accounted for 62%, 59% and 50%
of all cardiac events in the three groups, respectively, showing
a homogeneous stratification power of peak V˙O2 when only
these end points were considered.
The AT was not identified in 48 of the male patients (69%)
with a peak V˙O2 #10 ml/kg per min, 70 (42%) with a peak
V˙O2 .10 to 14 ml/kg per min, 40 (27%) with a peak V˙O2 .14
to 18 ml/kg per min and 23 (19%) with a peak V˙O2 .18 ml/kg
per min. There was no significant difference between the
survival curves for patients with a peak V˙O2 .10 to 14, .14 to
18 and .18 ml/kg per min (Fig. 3) for a cardiac event rate of
29%, 23% and 22% of 70, 40 and 23 subjects in each group,
respectively. However, the survival of patients with a peak
V˙O2 #10 ml/kg per min (22 [46%] of 48 patients with a cardiac
event) was markedly worse (p 5 0.007), indicating a high
predictive power of this peak V˙O2 level. When the survival
curve of this subgroup of patients was compared with that of
the corresponding subgroup with the same peak V˙O2 but a
measurable AT, substantial overlap of the two subgroups was
seen (p 5 0.52). For this reason, all 324 patients with a
detectable AT and 48 patients with an undetected AT but with
a peak V˙O2 #10 ml/kg per min were considered as a single
group (372 patients in all) in further analyses.
In this group of patients the survival of older (n 5 158) and
younger (n 5 214) subjects within the same peak V˙O2 cutoff
value was very similar (p . 0.5 for all comparisons) (Fig. 4).
The incidence of cardiac events was also comparable (Table 3).
For this reason, in the further analysis we did not consider age
groups separately.
When survival according to functional class at the time of
evaluation (235 patients in functional class I or II vs. 137
patients in functional class III or IV) (Table 3, Fig. 5) was
analyzed, different results were found depending on the value
of this clinical indicator. Peak V˙O2 cutoff values discriminated
well between low, medium and high risk patients in functional
class I or II, with mortality rates of 12%, 28% and 45%,
respectively (p 5 0.0005). The risk ratio was 2.5 (95% confi-
dence interval [CI] 1.2 to 5) between peak V˙O2 10 to 18 and
,10 ml/kg per min and 1.9 (95% CI 1.0 to 3.9) between peak
V˙O2 .18 and 10 to 18 ml/kg per min. In contrast, for patients
in functional class III or IV, all peak V˙O2 curves intersected
each other, and the log-rank test was not significant (p 5 0.15).
In the identified subgroup of patients in whom peak V˙O2
was a significant prognostic indicator (235 men in functional
class I or II), we verified the prognostic power of this marker
for short-, medium- and long-term outcome. The percent of
Figure 2. Survival curves for patients grouped
according to the cutoff values of Mancini et al.
(2). All patients had an identifiable AT. Cir-
cles 5 patients with a peak V˙O2 #10 ml/kg per
min; squares 5 patients with a peak V˙O2 .10
to 14 ml/kg per min; triangles 5 patients with
a peak V˙O2 .14 to 18 ml/kg per min; dia-
monds 5 patients with a peak V˙O2 .18 ml/kg
per min.
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event-free subjects at 6 months and 1 and 2 years is shown in
Table 4. It can be seen that a peak V˙O2 #10 ml/kg per min has
a prognostic power that persists over time, with a mortality rate
of 18% within 6 months, 36% within 1 year and 45% within 2
years. A peak V˙O2 10 to 18 ml/kg per min identified patients
with a poorer medium-term outcome than those with a peak
V˙O2 .18 ml/kg per min, who had the best prognosis up to 2
years.
Discussion
Peak V˙O2 has become an integral part of prognostic strat-
ification and evaluation for heart transplantation in patients
with chronic HF (2,13–19). However, validation of its clinical
applicability in a large population is still lacking, and the
simplistic (now widespread) use of its cutoff values in all
patients with moderate to severe chronic HF as a clinical tool
in decision making for heart transplantation might be inappro-
priate.
In the present study, we verified the prognostic value of
peak V˙O2 stratification, originally proposed by Mancini et al.
(2), in a large group of patients with moderate to severe
chronic HF consecutively considered for candidacy for heart
transplantation. We sought to exploit the information provided
by a few simple clinical indicators to apply peak V˙O2 cutoff
values more efficiently in the individual patient.
Contraindication to CPX testing. The present study veri-
fied that the presence of a clinical contraindication to perform-
ing the CPX test, despite optimized medical treatment, is the
simplest and strongest negative prognostic indicator. This
result confirms those previously demonstrated after acute
myocardial infarction (21), after lung cancer resection (22) and
in advanced HF (23).
By identifying patients with a high probability of an unfa-
vorable short-term outcome, the inability to perform an exer-
cise test is also a decisional indicator in the process of eligibility
for heart transplantation or ventricular assistance device im-
plantation. Accordingly, this indicator should be added to the
selection criteria for listing candidates with advanced HF and
for timing heart transplantation.
Prognostic power of the peak V˙O2 with and without detec-
tion of the AT. In patients able to perform an exercise test, the
peak V˙O2 cutoff points proposed by Mancini et al. (2) were
partially confirmed in our large cohort. A peak V˙O2 #10 ml/kg
per min identifies high risk patients, and a peak V˙O2 .18 ml/kg
Figure 3. Survival curves for patients grouped
according to the cutoff values of Mancini et al.
(2); no patient had an identifiable AT. Symbols
as in Figure 2.
Table 3. Cardiac Event Rates According to Peak Oxygen Uptake,
Age and Functional Class in Male Patients
Peak V˙O2
Age NYHA
#55 yr .55 yr I/II III/IV
,10 ml/kg per min
No. of patients 29 41 22 48
Cardiac event rate 48% 51% 45% 52%
10–18 ml/kg per min
No. of patients 115 91 127 79
Cardiac event rate 30% 35% 28% 39%
.18 ml/kg per min
No. of patients 70 26 86 10
Cardiac event rate 14% 15% 12% 40%
Abbreviations as in Table 1.
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per min identifies low risk patients; however, all other values in
between these cutoff values define a gray area of medium risk
patients, without any further possible stratification. This result
confirms the observations of Kao et al. (24) in 178 patients with
the same characteristics as ours. Moreover, our results do not
confirm the prognostic and decisional value of the “magic
Figure 4. Survival curves for patients
grouped according to peak V˙O2 and
age. Circles 5 patients with a peak
V˙O2 #10 ml/kg per min; squares 5
patients with a detectable AT and a
peak V˙O2 10 to 18 ml/kg per min;
triangles 5 patients with a detect-
able AT and a peak V˙O2 .18 ml/kg
per min.
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number” of 14 ml/kg per min of peak V˙O2 previously proposed
(5); for 10 to 18 ml/kg per min, such a cutoff point does not
discriminate patients at different risk.
In the Mancini et al. study (2), peak V˙O2 had prognostic
power provided that the AT was reached. When we performed
a survival analysis in the subgroup of our patients in whom the
Figure 5. Survival curves for patients
grouped according to peak V˙O2 and
New York Heart Association (NYHA)
functional class. Hash marks 5 pa-
tients with contraindications to exer-
cise testing; other symbols as in Fig-
ure 4.
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AT was not detected, we found that identification of the AT did
not influence the prognostic power of a peak V˙O2 #10 ml/kg
per min. The low level of symptom appearance is probably a
valuable indicator of abnormal metabolic response to exercise
and replaces the information of the low level of AT. This result
has important practical implications because the AT is not
detectable in the great majority of the patients with a peak V˙O2
#10 ml/kg per min (25–27) (Table 1) and, if reached, the AT
is hard to identify by noninvasive methods. Thus, the other
“magic number,” peak V˙O2 10 ml/kg per min should be taken
into account in the prognostic stratification of and decision
making for patients with chronic HF, without the constraint of
AT detection. In contrast, for all other patients without a
detectable AT and a peak V˙O2 .10 ml/kg per min, the peak
V˙O2 value does not provide prognostic information. In these
patients, a repeat exercise test is advisable.
Prognostic power of peak V˙O2 in the individual patient. To
individualize the use of peak V˙O2 as a prognostic and deci-
sional marker, gender, age and clinical severity were consid-
ered in the survival analysis. The first variable used to subgroup
patients was gender, in accordance with published suggestions
(19,28) of the limited prognostic power of peak V˙O2 in women
with HF and the poor informative results of exercise testing
previously seen in women with coronary disease (29–32).
Although our group of female transplant candidates is, to our
knowledge, the largest to be evaluated with exercise testing,
the sample size achieved was considered inadequate for a
reliable survival analysis to be performed. However, a major
finding was that women, compared with men, comprise both a
higher proportion of patients with low exercise capacity and
good prognosis and a lower proportion with a detectable AT.
In male patients grouped according to age (#55 vs. .55
years), no differences were seen in the prognostic power of
peak V˙O2 cutoff values. This result could be explained in part
by the absence of very elderly subjects among our transplant
candidates and in part by the observation that the strength of
the prognostic power of peak V˙O2 is concentrated at its lowest
and highest values (#10 and .18 ml/kg per min), which are far
more influenced by severity of functional limitations than by
age.
The prognostic power of peak V˙O2 was confirmed only in
patients in functional class I or II. Although the cardiac events
rate was higher in patients in functional class III or IV, survival
curves corresponding to the three peak V˙O2 strata were not
significantly different. Thus, peak V˙O2 shows less prognostic
sensitivity in those patients for whom decisional contributions
are most needed.
Short-, medium- and long-term prognostic power of peak
V˙O2. In summary, we found that peak V˙O2 provides prognostic
information in male patients with moderate to severe HF, who
are between 30 and 70 years old and are in functional class I or
II after optimal therapy. A peak V˙O2 .18 ml/kg per min
maintains its predictive power of a good outcome for at least 2
years. Thus, in these patients, repetition of the CPX test for
prognostic reasons might not be necessary throughout this
period. A peak V˙O2 #10 ml/kg per min shows a prognostic
power that is strong in the short term and is maintained over
time.
Toward the efficient use of peak V˙O2 in the individual
patient. The prognostic and decisional (evaluation for heart
transplantation) value of peak V˙O2 is summarized in Figure 6,
which may also be viewed as a flowchart for the efficient use of
Figure 6. Flowchart for efficient use of a cardiopulmonary exercise test
results in the individual patient with moderate to severe chronic HF.
NYHA 5 New York Heart Association.
Table 4. Percent of Event-Free Male Patients in Functional Class I
or II According to Peak Oxygen Uptake
Follow-Up Visit
Peak V˙O2 (ml/kg per min)
#10 10–18 .18
6 mo 82% 94% 99%
1 yr 64% 87% 98%
2 yr 54% 77% 92%
V˙O2 5 oxygen uptake.
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CPX test results in individual patients. A clear contraindica-
tion to exercise testing is both a prognostic and a decisional
indicator: The patient is at very high risk, and aggressive
treatment (i.e., urgent heart transplantation, ventricular assis-
tance) should be considered. When the CPX test is not
contraindicated and the patient is a woman, the current view is
that peak V˙O2 has little value for prognostic stratification and
decision making; however, larger studies are needed to confirm
this current provisional policy.
For male patients, CPX test results should be taken into
consideration in all subjects with a detectable AT and in those
who reach a peak V˙O2 #10 ml/kg per min without an evident
AT.
In patients in functional class III or IV, peak V˙O2 is neither
prognostic nor decisional. Our data are partially in contrast
with the results of Stevenson et al. (23), who showed that
among exercising patients in an advanced functional class, the
threshold of 10 ml/kg per min was the only cutoff value that
identified a higher risk group. Currently, most heart transplan-
tation centers rely heavily on peak V˙O2 evaluation to decide
which patients with advanced HF should be considered for
heart transplantation (12,18). We believe that this decision
should rely more on other indicators of prognosis, such as
contraindication to exercise testing and exhausted therapeutic
alternatives.
Male patients 30 to 70 years old, in functional class I or II
after optimal therapy and with a peak V˙O2 #10 ml/kg per min
have a cardiac event probability higher than all other patients
in functional class I or II and similar to that of patients in
functional class III or IV. Hence, in these patients peak V˙O2 is
a powerful decisional indicator for transplantation (and prior-
ity), whereas the simple evaluation of symptoms could be
misleading. These data are in agreement with those of Aaron-
son et al. (33), who showed that among ambulatory patients
referred for heart transplantation, peak V˙O2 alone gave a
satisfactory prognostic discrimination.
A patient with a peak V˙O2 .18 ml/kg per min, has a good
long-term prognosis. In this case, peak V˙O2 is also decisional,
making any aggressive treatment or close follow-up unneces-
sary.
Finally, patients with a peak V˙O2 in the range 10 to 18 ml/kg
per min fall into a gray (and unfortunately very large) prog-
nostic region, and peak V˙O2 does not provide information on
which decisions can be made. In such patients, further data
should be collected to improve prognostic capability and to
address decision making (e.g., serial cardiopulmonary exercise
tests, other exercise/recovery indexes [34,35]), evaluation of
responses to other therapy, other diagnostic tests [36]).
Conclusions. The results of the present study suggest that
the decision to list patients with advanced HF for heart
transplantation should rely not only on peak V˙O2 but on other
indicators of prognosis as well. Contraindication to exercise
testing appears to be a powerful short-term unfavorable prog-
nostic indicator. Only among less symptomatic male patients
able to exercise is peak V˙O2 a valuable prognostic indicator for
decision making in that it can identify low and high risk
subjects and thus offer a practical operative contribution for
nearly 20% of all patients with moderate to severe chronic HF.
For transplantation, only a peak V˙O2 #10 ml/kg per min is a
definite decisional indicator, with or without AT. These con-
siderations, together with the lack of prognostic power of peak
V˙O2 in patients in a functional class III or IV, limit its role in
clinical practice.
References
1. Cohn JN, Johnson GR, Shabetai R, et al., for the V-HeFT VA Cooperative
Studies Group. Ejection fraction, peak oxygen consumption, cardiothoracic
ratio, ventricular arrhythmias, and plasma norepinephrine as determinants
of prognosis in heart failure. Circulation 1993;87 Suppl VI:VI-5–16.
2. Mancini DM, Eisen H, Kussmaul W, Mull R, Edmunds LH, Wilson JR.
Value of peak exercise oxygen consumption for optimal timing of cardiac
transplantation in ambulatory patients with heart failure. Circulation 1991;
83:778–86.
3. Likoff MJ, Chandler SL, Kay HR. Clinical determinants of mortality in
chronic congestive heart failure secondary to idiopathic dilated or to
ischemic cardiomyopathy. Am J Cardiol 1987;59:634–8.
4. Parameshwar J, Keegan J, Sparrow J, Sutton GC, Poole-Wilson PA.
Predictors of prognosis in severe chronic heart failure. Am Heart J 1992;
123:421–6.
5. Pina IL. Optimal candidates for heart transplantation: is 14 the magic
number? J Am Coll Cardiol 1995;25:1143–53.
6. Roul G, Moulichon ME, Bareiss P, et al. Exercise peak VO2 determination
in chronic heart failure: is it still of value? Eur Heart J 1994;15:495–502.
7. Madsen BK, Hansen JF, Stokholm KH, Brons J, Husum D, Mortensen L.
Chronic congestive heart failure: description and survival of 190 consecutive
patients with a diagnosis of chronic congestive heart failure based on clinical
signs and symptoms. Eur Heart J 1994;15:303–10.
8. van den Broek S, van Veldhuisen D, de Graeff P, Landsman M, Hillege H,
Lie H. Comparison between New York Heart Association Classification and
peak oxygen consumption in the assessment of functional status and
prognosis in patients with mild to moderate chronic congestive heart failure
secondary to either ischemic or idiopathic dilated cardiomyopathy. Am J
Cardiol 1992;70:359–63.
9. Rickenbacher P, Trindade P, Haywood G, et al. Transplant candidates with
severe left ventricular dysfunction managed with medical treatment: charac-
teristics and survival. J Am Coll Cardiol 1996;27:1192–7.
10. Saxon L, Stevenson W, Middlekauff H, et al. Predicting death from
progressive heart failure secondary to ischemic or idiopathic dilated cardio-
myopathy. Am J Cardiol 1993;72:62–5.
11. Haywood G, Rickenbacher P, Trindade P, et al. Analysis of deaths in
patients awaiting heart transplantation: impact on patient selection criteria.
Heart 1996;75:455–62.
12. Hunt SA. Cardiac transplantation: the 24th Bethesda Conference. J Am Coll
Cardiol 1993;22:1–64.
13. Stevenson LW, Steimle A, Fonarow G, et al. Improvement in exercise
capacity of candidates awaiting heart transplantation. J Am Coll Cardiol
1995;25:163–70.
14. Singer A, Vagellos R, Wilson K, Nejedly M, Fowler M. Measurement of
maximal oxygen consumption is of value in the selection of patients for
cardiac transplantation [abstract]. J Am Coll Cardiol 1991;17 Suppl A:A57.
15. Stevenson LW. Selection and management of candidates for heart trans-
plantation. Current Opin Cardiol 1996;11:166–73.
16. Costanzo MR, Augustine S, Bourge R, et al. Selection and treatment of
candidates for heart transplantation. Circulation 1995;92:3593–612.
17. Kao W, Winkel E, Costanzo MR. Candidate evaluation and selection for
heart transplantation. Current Opin Cardiol 1995;10:159–68.
18. Miller L, Kuno S, Young J, Stevenson L, Loh E, Costanzo MR. Report of the
consensus conference on candidate selection for heart transplantation 1993.
J Heart Lung Transplant 1995;14:562–71.
19. Aaronson KD, Mancini DM. Is percentage of predicted maximal exercise
oxygen consumption a better predictor of survival than peak exercise oxygen
consumption for patients with severe heart failure? J Heart Lung Transplant
1995;14:981–9.
774 OPASICH ET AL. JACC Vol. 31, No. 4
PEAK V˙O2 IN THE INDIVIDUAL PATIENT March 15, 1998:766–75
20. Opasich C, Sisti M, Febo O, et al. Age limits for heart transplantation:
medical aspects. G Ital Cardiol 1997;27:557–62.
21. Villella A, Maggioni A, Villella M, et al. Prognostic significance of maximal
exercise testing after myocardial infarction treated with thrombotic agents:
the GISSI-2 data-base. Lancet 1995;346:523–9.
22. Epstein S, Faling J, Daly B, Celli B. Inability to perform bicycle ergometry
predicts increased morbidity and mortality after lung resection. Chest
1995;107:311–6.
23. Stevenson LW, Couper G, Natterson B, et al. Target heart failure popula-
tions for newer therapies. Circulation 1995;92 Suppl II:II-174–81.
24. Kao W, Winkel E, Johnson M, Piccione W, Lichtenberg R, Costanzo MT.
Role of maximal oxygen consumption in establishment of heart transplant
candidacy for heart failure patients with intermediate exercise tolerance.
Am J Cardiol 1997;79:1124–7.
25. Miyagi K, Asanoi H, Ishizaka S, Kameyama T, Sasayama S. Limited value of
anaerobic threshold for assessing functional capacity in patients with heart
failure. Clin Cardiol 1993;16:133–7.
26. Metra M, Raddino R, Dei Cas LD, Visioli O. Assessment of peak oxygen
consumption, lactate and ventilatory threshold and correlation with resting
and exercise hemodynamic data in chronic heart failure. Am J Cardiol
1990;65:1127–33.
27. Katz S, Berkowitz R, LeJemtel T. Anaerobic threshold detection in patients
with congestive heart failure. Am J Cardiol 1992;69:1565–9.
28. Stelken A, Younis L, Jennison S, et al. Prognostic value of cardiopulmonary
exercise testing using percent achieved of predicted peak oxygen uptake for
patients with ischemic and dilated cardiomyopathy. J Am Coll Cardiol
1996;27:345–52.
29. He ZX, Dakik HA, Vaduganathan P, Quereshi U, Mahmarian JJ, Verani
MS. Clinical and angiographic significance of a normal thallium-201 tomo-
graphic study in patients with a strongly positive exercise electrocardiogram.
Am J Cardiol 1996;78:638–41.
30. Hachamovitch R, Berman DS, Kiat H, et al. Effective risk stratification using
exercise myocardial perfusion SPECT in women: gender-related differences
in prognostic nuclear testing. J Am Coll Cardiol 1996;28:34–44.
31. Moriel M, Rozanski A, Klein J, Berman DS, Merz CN. The limited efficacy
of exercise radionuclide ventriculography in assessing prognosis of women
with coronary artery disease. Am J Cardiol 1995;76:1030–5.
32. Weiner DA, Ryan TJ, Parsons L, et al. Long-term prognostic value of
exercise testing in men and women from the Coronary Artery Surgery Study
(CASS) registry. Am J Cardiol 1995;75:865–70.
33. Aaronson K, Scwartz J, Chen T, Wong K, Goin J, Mancini D. Development
and prospective validation of a clinical index to predict survival in ambula-
tory patients referred for cardiac transplant evaluation. Circulation 1997;95:
2660–7.
34. Daida H, Allison T, Johnson B, Squires R, Gau G. Further increase in
oxygen uptake during early active recovery following maximal exercise in
chronic heart failure. Chest 1996;109:47–51.
35. DeGroote P, Millaire A, Decoulx E, Nugue O, Guimier P. Ducloux G.
Kinetics of oxygen consumption during and after exercise in patients with
dilated cardiomyopathy. J Am Coll Cardiol 1996;28:168–75.
36. Chomsky DB, Lang CC, Rayos GH, et al. Hemodynamic exercise testing: a
valuable tool in the selection of cardiac transplantation candidates. Circula-
tion 1996;94:3176–83.
775JACC Vol. 31, No. 4 OPASICH ET AL.
March 15, 1998:766–75 PEAK V˙O2 IN THE INDIVIDUAL PATIENT
